Antag Therapeutics ApS: Financial statements 2019
CVR: 38402056
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -7,866,664 and a net result of DKK -9,232,193 compared with DKK -4,429,240 the year before. Equity in the 2019 report amounted to DKK 2,584,196. The solvency ratio was 18.3%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -7,866,664
- Profit/Loss
- DKK -9,232,193
- Equity
- DKK 2,584,196
- Total Assets
- DKK 14,115,707
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -7.9M | -9.2M | 2.6M | 4 |
| 2018 | - | -3.1M | -4.4M | 11.8M | 4 |
| 2017 | - | -3.7M | -3.9M | 8.7M | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Antag Therapeutics ApS has published its annual report for 2018. Gross profit came to DKK -3,123,509, and the net result was DKK -4,429,240.
About Antag Therapeutics ApS
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.